• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    ADMA Biologics (ADMA) Slides Before Earnings, Is The Stock Still Undervalued?

    Simply Wall St·09/13/2026 04:24:47
    Listen to the news

    ADMA Biologics (ADMA) drew fresh attention after its share price fell 1.7% in the latest session, even as the S&P 500 gained 0.86% and investors looked ahead to upcoming earnings.

    For context, ADMA Biologics shares are trading at $9.23 after a 1-day share price decline of 1.7%, capping a 7-day drop of 4.1% and a 30-day fall of 2.5%. Over the same period, the 90-day share price return of 8.6% contrasts with a year-to-date slide of 48.4% and a 1-year total shareholder return decline of 42.7%. Longer term, total shareholder returns of about 147% over three years and more than 7x over five years reflect historical gains that investors are now weighing against expectations for the upcoming earnings report and the current forward P/E of 12.09 relative to the industry average.

    Spot opportunities around ADMA Biologics' pullback by scanning a curated group of quality stocks trading at a discount using the 31 high quality undervalued stocks.

    For ADMA Biologics, the pullback comes just as the market weighs an expected EPS of $0.19 and a forward P/E of 12.09. Is this dip about sentiment, or is it about what the business is really worth?

    Most Popular Narrative: 47.6% Undervalued

    Against ADMA Biologics' last close at $9.23, the most followed valuation narrative points to a fair value of $17.60, framing a sizeable gap that analysts connect to its plasma focused model and earnings profile.

    Commercial-scale implementation of the FDA-approved yield enhancement process is producing a 20%+ increase in bulk immunoglobulin output, expected to drive sustained gross margin expansion and higher net income starting in early 2026 and beyond.

    Read the complete narrative.

    Curious what kind of revenue path and profit trajectory underpin that fair value for ADMA Biologics. The narrative leans on brisk top line growth, rising margins and a future earnings multiple that assumes the market is willing to pay up for that combination. The detailed model threads these pieces together in a way the current share price does not fully reflect.

    Result: Fair Value of $17.60 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    Still, the ADMA Biologics story could be knocked off course if ASCENIV and BIVIGAM face tougher competition or if ongoing class action lawsuits weigh on sentiment.

    Find out about the key risks to this ADMA Biologics narrative.

    Next Steps

    If the ADMA Biologics story so far sounds compelling, pressure test it yourself and consider acting promptly while sentiment is still resetting around the latest moves. To zero in on what investors already like about the setup, review the 3 key rewards

    Looking for more ADMA Biologics style investment ideas?

    Do not stop with ADMA Biologics. Broaden your watchlist now so you are not scrambling later when the next opportunity shows up on everyone else's radar.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.